



<DATE>

<NAME>

<ADDRESS>

<CSZ>

Dear University of Arkansas Member,

In an effort to provide appropriate, affordable health care options while managing drug costs, the University of Arkansas prescription drug plan will move ONGLYZA to 100% copay status effective May 1 2018. As a result, you may see your copay increase. We suggest you speak with your physician about lower-cost alternatives (including over-the-counter) and the therapy most appropriate for your care

The above change to your prescription drug plan is directed by the University of Arkansas Pharmacy Advisory Committee, who strive to maintain affordable and appropriate healthcare benefits. The review of the DPP-4 inhibitor drug class (including Januvia, Janumet, Nesina, Oseno, Tradjenta, Jentadueto, Onglyza, Kombiglyze, and other combinations containing DPP4 inhibitors) showed the drugs provide no beneficial clinical outcomes compared to placebo. Although the drugs decrease hemoglobin A1C by a small amount, other drugs used to treat type 2 diabetes mellitus have shown to reduce the disease-related endpoints in type 2 diabetic patients. Please see your doctor to find which drug that has been shown to reduce cardiovascular disease and mortality is best for you. Alternatives include metformin, liraglutide (Victoza), empagliflozin (Jardiance) in some cases, and insulin.

If you have questions, please contact MedImpact Healthcare Systems, Inc. at 1-800-788-2949.

Sincerely,

MedImpact and the University of Arkansas Pharmacy Advisory Committee

The University of Arkansas' prescription drug formulary, administered by MedImpact, is maintained by the University of Arkansas System's Pharmacy Advisory Committee. The Pharmacy Advisory Committee is composed of U of A administrators, AON Hewitt Consultants, Med Impact-PBM vendors, and both faculty and clinical pharmacists, who advise the Committee on the most recent medical research results. The recommendations by the committee are based on the latest available evidence-based studies.